NCT06490562View on ClinicalTrials.gov

Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI

NANot yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

May 31, 2028

Study Completion Date

December 31, 2028

Conditions
Acute Graft-versus-host Disease
Interventions
DRUG

PDCy

Low dose Cy 30 mg/kg/d was administered on the 3rd and 4th day after gDLI to prevent GVHD

DRUG

Non Cy

Oral administration of low-dose CNI (CSA 25mg Q12H or FK506 0.25mg Q12H combined with azole fungal drugs) for 2 weeks to prevent GVHD at 0 days after gDLI

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06490562 - Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI | Biotech Hunter | Biotech Hunter